 Fluorouracil
"Fluorouracil" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
| Descriptor ID |
D005472
|
| MeSH Number(s) |
D03.383.742.698.875.404
|
| Concept/Terms |
Fluorouracil- Fluorouracil
- 5-FU
- Fluoruracil
- 5-Fluorouracil
- 5 Fluorouracil
- 5FU
5-FU medac- 5-FU medac
- 5 FU medac
- medac Brand of Fluorouracil
5-HU Hexal- 5-HU Hexal
- 5 HU Hexal
- Hexal Brand of Fluorouracil
Adrucil- Adrucil
- Teva Brand of Fluorouracil
- Fluorouracil Teva Brand
Carac- Carac
- Dermik Brand of Fluorouracil
Efudix- Efudix
- Dermatech Brand of Fluorouracil
- Roche Brand of Fluorouracil
- Fluoro-Uracile ICN
- Fluoro Uracile ICN
- ICN Brand of Fluorouracil
- CSP Brand of Fluorouracil
- Efudex
Fluoroplex- Fluoroplex
- Flurodex
- Allergan Brand of Fluorouracil
Fluracedyl- Fluracedyl
- Pharmachemie Brand of Fluorouracil Monosodium Salt
Haemato-fu- Haemato-fu
- Haemato fu
- Haemato Brand of Fluorouracil
Neofluor- Neofluor
- Neocorp Brand of Fluorouracil
Onkofluor- Onkofluor
- Onkoworks Brand of Fluorouracil
Ribofluor- Ribofluor
- ribosepharm Brand of Fluorouracil
5-FU Lederle- 5-FU Lederle
- 5 FU Lederle
- Riemser Brand of Fluorouracil
|
Below are MeSH descriptors whose meaning is more general than "Fluorouracil".
Below are MeSH descriptors whose meaning is more specific than "Fluorouracil".
This graph shows the total number of publications written about "Fluorouracil" by people in this website by year, and whether "Fluorouracil" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1981 | 1 | 0 | 1 | | 1982 | 0 | 1 | 1 | | 1983 | 0 | 2 | 2 | | 1984 | 0 | 1 | 1 | | 1986 | 2 | 1 | 3 | | 1988 | 0 | 4 | 4 | | 1989 | 1 | 4 | 5 | | 1990 | 2 | 5 | 7 | | 1991 | 1 | 3 | 4 | | 1992 | 5 | 5 | 10 | | 1993 | 3 | 3 | 6 | | 1994 | 2 | 5 | 7 | | 1995 | 1 | 7 | 8 | | 1996 | 2 | 8 | 10 | | 1997 | 1 | 4 | 5 | | 1998 | 4 | 6 | 10 | | 1999 | 4 | 6 | 10 | | 2000 | 3 | 8 | 11 | | 2001 | 5 | 7 | 12 | | 2002 | 7 | 9 | 16 | | 2003 | 7 | 5 | 12 | | 2004 | 5 | 7 | 12 | | 2005 | 3 | 8 | 11 | | 2006 | 2 | 8 | 10 | | 2007 | 0 | 7 | 7 | | 2008 | 2 | 3 | 5 | | 2009 | 4 | 3 | 7 | | 2010 | 1 | 8 | 9 | | 2011 | 0 | 11 | 11 | | 2012 | 3 | 12 | 15 | | 2013 | 2 | 8 | 10 | | 2014 | 4 | 9 | 13 | | 2015 | 2 | 4 | 6 | | 2016 | 1 | 5 | 6 | | 2017 | 1 | 5 | 6 | | 2018 | 0 | 4 | 4 | | 2019 | 1 | 5 | 6 | | 2020 | 2 | 2 | 4 |
To return to the timeline, click here.
Below are the most recent publications written about "Fluorouracil" by people in Profiles.
-
Islam R, Khan R, Ali A, Kollu V, Phan T, Chyou PH, Burmester JK, Kibriya MG. Clinical Factors Affecting Bevacizumab Efficacy With and Without Conventional Chemotherapy in Metastatic Colon Cancer. Am J Ther. 2020 Sep/Oct; 27(5):e500-e506.
-
Sharma MR, Joshi SS, Kindler HL. 5-FU, Irinotecan, Nab-Paclitaxel in Gastrointestinal Cancers-Response. Clin Cancer Res. 2020 07 15; 26(14):3890.
-
Di Bartolomeo M, Raimondi A, Cecchi F, Catenacci DVT, Schwartz S, Sellappan S, Tian Y, Miceli R, Pellegrinelli A, Giommoni E, Aitini E, Spada F, Rosati G, Marchet A, Pucci F, Zaniboni A, Tamberi S, Pressiani T, Sanna G, Cantore M, Mosconi S, Bolzoni P, Pinto C, Landi L, Soto Parra HJ, Cavanna L, Corallo S, Martinetti A, Hembrough TA, Pietrantonio F. Association of high TUBB3 with resistance to adjuvant docetaxel-based chemotherapy in gastric cancer: translational study of ITACA-S. Tumori. 2021 Apr; 107(2):150-159.
-
Catenacci DVT, Chase L, Lomnicki S, Karrison T, de Wilton Marsh R, Rampurwala MM, Narula S, Alpert L, Setia N, Xiao SY, Hart J, Siddiqui UD, Peterson B, Moore K, Kipping-Johnson K, Markevicius U, Gordon B, Allen K, Racette C, Maron SB, Liao CY, Polite BN, Kindler HL, Turaga K, Prachand VN, Roggin KK, Ferguson MK, Posner MC. Evaluation of the Association of Perioperative UGT1A1 Genotype-Dosed gFOLFIRINOX With Margin-Negative Resection Rates and Pathologic Response Grades Among Patients With Locally Advanced Gastroesophageal Adenocarcinoma: A Phase 2 Clinical Trial. JAMA Netw Open. 2020 02 05; 3(2):e1921290.
-
Joshi SS, Catenacci DVT, Karrison TG, Peterson JD, Zalupski MM, Sehdev A, Wade J, Sadiq A, Picozzi VJ, Amico A, Marsh R, Kozloff MF, Polite BN, Kindler HL, Sharma MR. Clinical Assessment of 5-Fluorouracil/Leucovorin, Nab-Paclitaxel, and Irinotecan (FOLFIRABRAX) in Untreated Patients with Gastrointestinal Cancer Using UGT1A1 Genotype-Guided Dosing. Clin Cancer Res. 2020 01 01; 26(1):18-24.
-
Muss HB, Polley MC, Berry DA, Liu H, Cirrincione CT, Theodoulou M, Mauer AM, Kornblith AB, Partridge AH, Dressler LG, Cohen HJ, Kartcheske PA, Perez EA, Wolff AC, Gralow JR, Burstein HJ, Mahmood AA, Sutton LM, Magrinat G, Parker BA, Hart RD, Grenier D, Hurria A, Jatoi A, Norton L, Hudis CA, Winer EP, Carey L. Randomized Trial of Standard Adjuvant Chemotherapy Regimens Versus Capecitabine in Older Women With Early Breast Cancer: 10-Year Update of the CALGB 49907 Trial. J Clin Oncol. 2019 09 10; 37(26):2338-2348.
-
Rosenberg AJ, Rademaker A, Hochster HS, Ryan T, Hensing T, Shankaran V, Baddi L, Mahalingam D, Mulcahy MF, Benson AB. Docetaxel, Oxaliplatin, and 5-Fluorouracil (DOF) in Metastatic and Unresectable Gastric/Gastroesophageal Junction Adenocarcinoma: A Phase II Study with Long-Term Follow-Up. Oncologist. 2019 08; 24(8):1039-e642.
-
Catenacci DV, Tesfaye A, Tejani M, Cheung E, Eisenberg P, Scott AJ, Eng C, Hnatyszyn J, Marina N, Powers J, Wainberg Z. Bemarituzumab with modified FOLFOX6 for advanced FGFR2-positive gastroesophageal cancer: FIGHT Phase III study design. Future Oncol. 2019 Jun; 15(18):2073-2082.
-
Bang YJ, Kang YK, Catenacci DV, Muro K, Fuchs CS, Geva R, Hara H, Golan T, Garrido M, Jalal SI, Borg C, Doi T, Yoon HH, Savage MJ, Wang J, Dalal RP, Shah S, Wainberg ZA, Chung HC. Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 study. Gastric Cancer. 2019 07; 22(4):828-837.
-
Sharma MR, Joshi SS, Karrison TG, Allen K, Suh G, Marsh R, Kozloff MF, Polite BN, Catenacci DVT, Kindler HL. A UGT1A1 genotype-guided dosing study of modified FOLFIRINOX in previously untreated patients with advanced gastrointestinal malignancies. Cancer. 2019 05 15; 125(10):1629-1636.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|